Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
12 min read
Arnold-Chiari Malformation Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Arnold-Chiari Malformation in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Dandy-Walker Syndrome Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Dandy-Walker Syndrome with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Agenesis of Cerebellar Vermis Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Agenesis of Cerebellar Vermis in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Spinocerebellar Degenerations Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Spinocerebellar Degenerations in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Ataxia With Vitamin E Deficiency Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Ataxia With Vitamin E in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Spinocerebellar Ataxia 31 Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Spinocerebellar Ataxia 31 in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Episodic Ataxia, Type 6 Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Episodic Ataxia, Type 6 in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Myoclonic Epilepsies, Progressive Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Myoclonic Epilepsies in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Neuronal Intranuclear Inclusion Disease Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Neuronal Intranuclear in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Xanthomatosis, Cerebrotendinous Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Xanthomatosis in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Dysarthria Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Dysarthria with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Hereditary Sensory and Motor Neuropathy Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Hereditary Sensory and Motor in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.